Bayer nabs FDA approval for topical heartworm drug; BI sells veterinary manufacturing plant to Argenta; CWD found in captive Texas deer;

> The FDA approved Bayer's Coraxis, a topical treatment for the prevention of heartworm and the treatment of hookworms, roundworms, and whipworms. Document (PDF)

> New Zealand's Argenta acquired a manufacturing facility from Boehringer Ingelheim Vetmedica that's located in Fort Dodge, IA. Release

> A two-year-old white-tailed deer at a captive breeding facility in Medina County, TX, was diagnosed with Chronic Wasting Disease (CWD), prompting an investigation into the risk of CWD among free-ranging and captive deer and elk in the area. Article

> VaxLiant won approval from the USDA for three new adjuvants for use in poultry vaccines. Release

> Scientists at University of Pittsburgh Center for Vaccine Research received $4 million in federal grants to study a group of mosquito-borne illnesses, including eastern equine encephalitis virus (EEEV), which can be transmitted to both horses and people. Release

> Australia's Anatara Lifesciences raised $7 million in capital to develop Detach, its lead compound to prevent diarrhea in pigs and other livestock. Release (PDF)

> An international research team led by the University of Virginia School of Medicine received $1.35 million from the Human Frontier Science Program Organization to study how avian flu passes from birds to humans. Release